Trump Announces Argentina-U.S. Tariff Elimination
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.TARIFFS:The Argentine foreign ministry posted aon X to announce a reciprocal trade and investment agreement between Argentina and the United States. The U.S. will eliminate reciprocal tariffs for 1,675 Argentine products and the U.S. government also committed to a timely review of tariffs on steel and aluminum, according to the statement.DRUG DISCOUNT SITE:President Trump is expected to announce the launch of the TrumpRx website, an adviser told Axios, moving ahead with a plan to offer discounted drug prices through special agreements with drug companies, Axios' Marc Caputo. The launch will allow people to buy medications directly through the new government portal with discounts the White House has negotiated with the drug manufacturers, the author notes. The announcement is scheduled for 7pm ET. The site will offer discounts on drugs from major drug companies including Pfizer, AstraZeneca, EMD Serono, Eli Lillyand Novo Nordisk, according to the publication.Meanwhile, STAT News' Elaine Chen, John Wilkerson, and Chelsea Cirruzzothat the website is expected to display the cash prices for certain drugs and direct patients to other sites where they can buy the therapies, but some experts are skeptical the platform will meaningfully affect affordability, the report noted. Publicly traded large cap drugmakers include AstraZeneca, Bristol Myers, Eli Lilly, GSK, Johnson & Johnson, Merck, Novartis, Pfizer, Rocheand Sanofi.Pfizer has since "announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting today, the program provides Americans a wide range of more than 30 medicines at a significant discount off list prices. This effort is part of Pfizer's broader landmark Most Favored Nation agreement with the U.S. government enabling patients to pay lower prices for their prescription medicines, while strengthening America's role as a global leader in pharmaceutical innovation." Through the TrumpRx platform, uninsured or insured American patients who choose to self-pay outside of insurance will be offered savings that range as high as 85%, and on average 50%, for the large majority of Pfizer's primary care treatments and select specialty brands, the company said. Pfizer will also continue to expand PfizerForAll, a direct-to-consumer platform launched in 2024.CHINA ORDERS FOR BOEING:Jefferies keeps a Buy rating on Boeingwith a $295 price target saying President Trump wrote on social media about positive phone call with China President Xi ahead of his trip in April. The post directly mentions aircraft and engines, which could be a signal for China's first Boeing 737 orders since 2017, the firm tells investors in a research note. Jefferies points out that China accounted for 21% of Boeing's deliveries from 2010-2019.
Trade with 70% Backtested Accuracy
Analyst Views on PFE
About PFE
About the author
PFIZER - FDA SCHEDULES PDUFA DECISION DATE FOR HYMPAVZI IN SECOND QUARTER OF 2026
FDA Action Date: The FDA has set an action date for the approval of HYMPAZIV, which is scheduled for the second quarter of 2026.
HYMPAZIV Overview: HYMPAZIV is a medication developed by Pfizer, indicating ongoing advancements in pharmaceutical treatments.
FDA Approves Priority Review for HYMPAVZI® (Marstacimab) SBLA to Address Significant Medical Needs in Hemophilia A and B Patients
FDA Grants Priority Review: The FDA has granted priority review for the treatment of two patient populations with significant medical needs using HYM-PAVZ® (MARS-TACIMAB).
Focus on Hemophilia A: The review specifically targets patients with Hemophilia A, indicating a critical advancement in treatment options for this condition.
Pfizer Launches TrumpRx Program to Reduce Drug Costs
- Significant Drug Price Reductions: Pfizer's launch of the TrumpRx program offers substantial discounts on over 30 medications, with savings up to 85% and an average of 50%, aimed at alleviating the financial burden on American patients and enhancing their access to healthcare.
- Historic Agreement Support: This initiative is part of Pfizer's landmark Most Favored Nation agreement with the Trump administration, designed to lower prescription drug prices for U.S. patients while reinforcing America's leadership in global pharmaceutical innovation.
- Broad Patient Benefits: More than 100 million patients will benefit from discounted access to these medications, which treat a variety of conditions including migraines, rheumatoid arthritis, and menopause, significantly improving their quality of life and healthcare options.
- Enhanced Partnerships: Pfizer's collaboration with GoodRx allows patients to use coupons at nearly any U.S. pharmacy or opt for home delivery services, further increasing flexibility and convenience in accessing medications.
Healthcare Sector Earnings Overview
- Earnings Progress: As of February 6, 23 healthcare companies reported earnings, bringing the sector's overall reporting progress to 38%, indicating stability in industry performance and heightened investor interest.
- Pfizer Earnings Highlight: Pfizer (PFE) posted a strong Q4 with revenue of $17.6 billion, exceeding expectations; however, its shares fell due to projected revenue contraction in 2026, reflecting market concerns about future growth.
- AbbVie Outperformance: AbbVie (ABBV) reported revenue of $16.62 billion and earnings per share of $2.71, surpassing Wall Street forecasts, driven by strong performance from its flagship product Humira, with a projected total sales growth of 9.5% for the year, boosting market confidence.
- Merck's Dismal Outlook: Merck (MERK) reported a solid Q4 with revenue of $16.4 billion and EPS of $2.04, both beating expectations; however, its 2026 outlook fell short of Wall Street estimates, leading to a decline in share price and reflecting cautious market sentiment regarding future growth.
Pfizer CEO Discusses Progress on Weight-Loss Drugs
- Weight-Loss Drug Development: Pfizer's GLP-1 weight-loss drug is targeted for market entry in 2028, with CEO Albert Bourla stating that the 9.6 mg high dose will be tested in phase three trials, predicting that weight loss at week 28 will surpass competitors.
- Market Demand Analysis: Despite the popularity of GLP-1 medications, 40% to 50% of patients discontinue use within a year, particularly among those over 65, indicating a significant unmet medical need in the market.
- Diverse Product Portfolio: Pfizer's portfolio includes monthly and quarterly injectable medications that combine GLP-1 and Amylin, aiming to enhance patient tolerability and convenience, thereby strengthening its competitive position.
- Strategic Positioning: Pfizer plans to leverage its diverse injectable and oral drug combinations, utilizing the company's robust R&D capabilities to aim for a leading role in the rapidly growing weight-loss drug market.
TrumpRx Launches, But Few Will Reap Its Benefits.
Limited Initial Benefits: Only a small segment of consumers is expected to benefit from the TrumpRx initiative aimed at reducing drug costs.
Expert Opinions: Experts suggest that the initiative may not provide widespread relief for all Americans regarding prescription drug prices.
PFIZER - FDA SCHEDULES PDUFA DECISION DATE FOR HYMPAVZI IN SECOND QUARTER OF 2026
FDA Action Date: The FDA has set an action date for the approval of HYMPAZIV, which is scheduled for the second quarter of 2026.
HYMPAZIV Overview: HYMPAZIV is a medication developed by Pfizer, indicating ongoing advancements in pharmaceutical treatments.
FDA Approves Priority Review for HYMPAVZI® (Marstacimab) SBLA to Address Significant Medical Needs in Hemophilia A and B Patients
FDA Grants Priority Review: The FDA has granted priority review for the treatment of two patient populations with significant medical needs using HYM-PAVZ® (MARS-TACIMAB).
Focus on Hemophilia A: The review specifically targets patients with Hemophilia A, indicating a critical advancement in treatment options for this condition.
Pfizer Launches TrumpRx Program to Reduce Drug Costs
- Significant Drug Price Reductions: Pfizer's launch of the TrumpRx program offers substantial discounts on over 30 medications, with savings up to 85% and an average of 50%, aimed at alleviating the financial burden on American patients and enhancing their access to healthcare.
- Historic Agreement Support: This initiative is part of Pfizer's landmark Most Favored Nation agreement with the Trump administration, designed to lower prescription drug prices for U.S. patients while reinforcing America's leadership in global pharmaceutical innovation.
- Broad Patient Benefits: More than 100 million patients will benefit from discounted access to these medications, which treat a variety of conditions including migraines, rheumatoid arthritis, and menopause, significantly improving their quality of life and healthcare options.
- Enhanced Partnerships: Pfizer's collaboration with GoodRx allows patients to use coupons at nearly any U.S. pharmacy or opt for home delivery services, further increasing flexibility and convenience in accessing medications.
Healthcare Sector Earnings Overview
- Earnings Progress: As of February 6, 23 healthcare companies reported earnings, bringing the sector's overall reporting progress to 38%, indicating stability in industry performance and heightened investor interest.
- Pfizer Earnings Highlight: Pfizer (PFE) posted a strong Q4 with revenue of $17.6 billion, exceeding expectations; however, its shares fell due to projected revenue contraction in 2026, reflecting market concerns about future growth.
- AbbVie Outperformance: AbbVie (ABBV) reported revenue of $16.62 billion and earnings per share of $2.71, surpassing Wall Street forecasts, driven by strong performance from its flagship product Humira, with a projected total sales growth of 9.5% for the year, boosting market confidence.
- Merck's Dismal Outlook: Merck (MERK) reported a solid Q4 with revenue of $16.4 billion and EPS of $2.04, both beating expectations; however, its 2026 outlook fell short of Wall Street estimates, leading to a decline in share price and reflecting cautious market sentiment regarding future growth.
Pfizer CEO Discusses Progress on Weight-Loss Drugs
- Weight-Loss Drug Development: Pfizer's GLP-1 weight-loss drug is targeted for market entry in 2028, with CEO Albert Bourla stating that the 9.6 mg high dose will be tested in phase three trials, predicting that weight loss at week 28 will surpass competitors.
- Market Demand Analysis: Despite the popularity of GLP-1 medications, 40% to 50% of patients discontinue use within a year, particularly among those over 65, indicating a significant unmet medical need in the market.
- Diverse Product Portfolio: Pfizer's portfolio includes monthly and quarterly injectable medications that combine GLP-1 and Amylin, aiming to enhance patient tolerability and convenience, thereby strengthening its competitive position.
- Strategic Positioning: Pfizer plans to leverage its diverse injectable and oral drug combinations, utilizing the company's robust R&D capabilities to aim for a leading role in the rapidly growing weight-loss drug market.
TrumpRx Launches, But Few Will Reap Its Benefits.
Limited Initial Benefits: Only a small segment of consumers is expected to benefit from the TrumpRx initiative aimed at reducing drug costs.
Expert Opinions: Experts suggest that the initiative may not provide widespread relief for all Americans regarding prescription drug prices.
